Andrea Necchi, ESMO 2019 – KEYNOTE-045 trial in advanced urothelial cancer
We met with Andrea Necchi (Fondazione IRCCS Istituto Nazionale dei Tumori) at ESMO 2019 to discuss the 3-year follow-up results from the phase III KEYNOTE-045 trial: Pembrolizumab Versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer (NCT02256436).
1. What are the limitations of the current standard of care for the second-line treatment of patients with recurrent urothelial cancer? (0:05)
2. Could you tell us a little about the aims and design of the KEYNOTE-045 study? (3:44)
3. What is the role of programmed death-ligand 1 (PD-L1) expression in predicting response? (6:02)
4. What future studies of pembrolizumab in urothelial cancer are planned? (7:36)
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
Speaker disclosure: Andrea Necchi has received honoraria from Roche, Merck, AstraZeneca, Janssen, and Foundation Medicine; has served as a consultant/advisor for Merck Sharp & Dohme, Roche, Bayer, AstraZeneca, Clovis Oncology, Janssen, Incyte, Seattle Genetics/Astellas, Bristol-Myers Squibb, and Rainier Therapeutics; has received institutional research funding from Merck Sharp & Dohme and AstraZeneca; has received travel expenses from Roche, Merck Sharp & Dohme, AstraZeneca, Janssen, and Rainier Therapeutics; and has an immediate family member who has other relationships with Bayer.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Genitourinary Cancer
Sebastian Schmid, ESMO 2022: RACE-IT – RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in advanced bladder cancer
Patients with locally advanced bladder cancer have a poor prognosis despite surgical therapy. Prof. Sebastian Schmid (Technical University of Munich, Munich, Germany) joins touchONCOLOGY to discuss the unmet needs in the treatment of locally advanced bladder cancer, and also discusses the feasibility, safety and efficacy of neoadjuvant radio-immunotherapy following radical cystectomy in patients with locally […]
Jonathan Rosenberg, ESMO 2022: Study EV-103 Cohort K – Enfortumab vedotin in combination with pembrolizumab in locally advanced or metastatic urothelial cancer
As there is a current need for effective and tolerable first line treatment options in patients with locally advanced or metastatic urothelial cancer (la/mUC), Dr Jonathan Rosenberg (Memorial Sloan Kettering Cancer Center, New York, NY, USA) joins touchONCOLOGY to discuss the positive results from Study EV-103 Cohort K. The study data supports ongoing investigations of […]
Enrique Grande, ESMO 2022: Post-hoc analysis investigating PD-L1 expression on immune cells, and improved OS with atezolizumab in patients with urothelial cancer
PD-L1 assays use various methods to predict PD-L1/PD-1 blockade outcomes, recent data suggests clinically relevant PD-L1–expressing immune cells are dendritic cells. Dr Enrique Grande Pulido (MD Anderson Cancer Centre Madrid, Madrid, Spain) joins touchONCOLOGY to discuss a post-hoc analysis investigating PD-L1 expression on immune cells by SP142 co-localises with dendritic cells, and the associated improved overall […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!